SpaceX IPO Access Restrictions Signal Deeper US-China Capital Market Fragmentation

The exclusion of China- and Hong-Kong-based investors from SpaceX's planned $75 billion listing, as reported by Bloomberg via underwriters Goldman Sachs and JPMorgan, extends beyond routine compliance into the mechanics of outbound investment screening. Primary records from the Committee on Foreign Investment in the United States (CFIUS) annual reports document a steady rise in reviews of dual-use aerospace transactions since Executive Order 14083 expanded national-security criteria in 2022. This pattern intersects with the 2023 Treasury outbound-investment executive order, which formalizes prohibitions on US persons facilitating certain PRC semiconductor and AI-related flows, creating compliance friction even for equity offerings in non-listed entities. Chinese regulatory filings, including SAFE circulars on overseas securities investment, illustrate reciprocal tightening that limits domestic institutions' participation in US offerings. Coverage in secondary outlets overlooks how these restrictions interact with the CHIPS and Science Act's supply-chain mandates, effectively converting private-market access into an extension of export-control regimes. Multiple perspectives emerge: US officials frame the measures as safeguarding critical technologies, while PRC state media emphasize discriminatory barriers that accelerate parallel capital-market development in Asia. Primary source analysis shows the IPO restrictions align with documented increases in rejected transactions involving Hong Kong entities post-2020 national-security law.